In comparison with KRAS MAF in ctDNA, there was no statistically significant difference in KRAS MAF in tumor tissue, when the PC patients were stratified with either clinical staging or the presence of distant metastasis (Table 3, Figure 2B, p = 0.498 and 0.370). The gene discussed is KRAS; the disease is neoplasm.